Nair DR, Laxer KD, Weber PB et al. Nine-Year Prospective Efficacy And Safety Of Brain-Responsive Neurostimulation For Focal Epilepsy. Neurology. 2020 Sep 1;95(9):e1244-e1256. doi: 10.1212/WNL.0000000000010154. Epub 2020 Jul 20. PubMed PMID: 32690786; PubMed Central PMCID: PMC7538230.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. PubMed PMID: 32757523

Vagal Nerve Stimulation (VNS) in genetic developmental epileptic encephalopathies (DEE): approach in highly specialized centers around the world. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. Epilepsia Supplements December, 2020

Use of a Second Dose of Diazepam Nasal Spray Within 4 Hours and Effect on the Safety Profile in Patients with Seizure Clusters: Interim Results from a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study.  Daniel Tarquinio, Eric B. Segal, Ian Miller, James W. Wheless, R. Edward Hogan, Victor Biton, Gregory D. Cascino, Michael R. Sperling, Kore Liow, Blanca Vazquez, Ricardo Ayala, Weldon Mauney, Jay Desai, Adrian L. Rabinowicz, Enrique Carrazana, for the DIAZ.001.05 Study Group. Epilepsia Supplements December, 2020

Efficacy and Safety Of Adjunctive Padsevonil In Adults With Drug-Resistant Focal Seizures: A Double-Blind, Randomized, Placebo-Controlled Dose-Finding Trial.  Rademacher M, Toledo M, Van Paesschen W, Liow K, Esch M, Webster E, Wang N, Werhahn K, French J. Epilepsia Supplements December, 2020

Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study.   Eric B. Segal, ; Daniel Tarquinio, Ian Miller, James W. Wheless, Dennis Dlugos, Ricardo Ayala,Victor Biton, Gregory D. Cascino, Jay Desai, R. Edward Hogan, Kore Liow, Weldon Mauney, Michael R. Sperling, Blanca Vazquez, David F. Cook, Adrian L. Rabinowicz, Enrique Carrazana for the DIAZ.001.05 Study Group. Epilepsia Supplements December, 2020

CORE-VNS: A Prospective Outcomes Registry of Patients With Drug-resistant Epilepsy Treated With Vagus Nerve Stimulation Therapy.   Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020. Epilepsia Supplements December, 2020

Wessels AM, Barbone JM, DiGregorio DT, Miller DS, Mullen JA, Sims JR. Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study. CTAD Poster Abstract. J Prev Alzheimers Dis. 2018; 5(Supp 1):S188-S189

Two-Part, Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Patients with Epilepsy with a Predictable Seizure Pattern: Results from the Initial Open-Label Feasibility Part.  J French, K Liow, B Vazquez, P Klein, D Tarquinio, B Reich, R Small, J Isojarvi. Neurology Supplements 2019

Frank Nagy, Michael A. Rogawski, Hui Gong, Kore Liow, Sami Aboumater, Pavel Klein, Michael A. Gelfand, Cassie Jung, Stephen Wargacki, Rikin Mehta, Allen H. heller Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy: Comparison of Bioavailability with Periictal and Interictal Administration.  Neurotherapeutics 2019.

Safety Profile of Valtoco® (diazepam nasal spray) in Patients with Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Managed Care Pharmacist (AMCP) Annual Meeting, Virtual. April 2021

Time to Second Doses in Emergency Seizure Patients Treated with Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Managed Care Pharmacist (AMCP) Annual Meeting, Virtual. April 2021

Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study. Segal E, Tarquinio D, Miller I, Wheless J, Dlugos D, Biton V, Cascino G, Desai J, Hogan E, Liow K, Mauney W, Sperling M, Cook D, Rabinowicz A, Carrazana E, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021

Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021

Time to Second Doses in Emergency Seizure Patients Treated with Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021

Use of a Second Dose of Diazepam Nasal Spray Within 4 Hours and Effect on the Safety Profile in Patients with Seizure Clusters: Interim Results from a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study.  Daniel Tarquinio, Eric B. Segal, Ian Miller, James W. Wheless, R. Edward Hogan, Victor Biton, Gregory D. Cascino, Michael R. Sperling, Kore Liow, Blanca Vazquez, Ricardo Ayala, Weldon Mauney, Jay Desai, Adrian L. Rabinowicz, Enrique Carrazana, for the DIAZ.001.05 Study Group. 74^th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.

Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study.   Eric B. Segal, ; Daniel Tarquinio, Ian Miller, James W. Wheless, Dennis Dlugos, Ricardo Ayala,Victor Biton, Gregory D. Cascino, Jay Desai, R. Edward Hogan, Kore Liow, Weldon Mauney, Michael R. Sperling, Blanca Vazquez, David F. Cook, Adrian L. Rabinowicz, Enrique Carrazana for the DIAZ.001.05 Study Group. 74^th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.

Efficacy and Safety Of Adjunctive Padsevonil In Adults With Drug-Resistant Focal Seizures: A Double-Blind, Randomized, Placebo-Controlled Dose-Finding Trial.  Rademacher M, Toledo M, Van Paesschen W, Liow K, Esch M, Webster E, Wang N, Werhahn K, French J. 74^th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.

Vagal Nerve Stimulation (VNS) in genetic developmental epileptic encephalopathies (DEE):approach in highly specialized centers around the world. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020 74^th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.

CORE-VNS: A Prospective Outcomes Registry of Patients With Drug-resistant Epilepsy Treated With Vagus Nerve Stimulation Therapy.   Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020 74^th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.

A Randomized Phase 3 Study in Mild Alzheimer’s Disease (DAYBREAK-ALZ). Sims JR, Zimmer J, Wessels A, Selzler K, Andersen SW, Landry J, Mullen J, Barker P, Stern R, Vellas B, Boada M, Cohen S, MacSweeny E, Tariot P. Lanabecestat.  14th International Conference on Alzheimer’s and Parkinson’s Disease (ADPD) 2019.

Use of Cannabinoids in Patients with Epilepsy from a Comprehensive Epilepsy Center in Hawaii. R Ho, J Zhang, C Lu, B Fong, K Oura, A Shipman, H Hu, A Appana, G Slattery, E Carrazana , K Liow,  American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019

Biopsychological predictors in patients with psychogenic non-epileptic seizures from a comprehensive epilepsy center in Hawai’i, ,C Lu, R Ho, J Ocol, M Yang, E Carrazana, K Liow American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019 

Willis B, James D, Scott S, Bragg S, Mullen J, Downing A, Selzler K, Wessels A, Zimmer J, Sims J. Lanabecestat: Biomarker results from two Phase 3 studies in Alzheimer’s disease. 14th International Conference on Alzheimer’s and Parkinson’s Disease (ADPD) 2019.

 Mintun M, Shcherbinin S, Charil A, Zimmer J, Andersen S, Landry J, Mullen J, Wessels A, Bragg S, Selzler K, Fleisher A, Sims J. Lanabecestat:  Neuroimaging results from two Phase 3 studies in Alzheimer’s disease. 14th International Conference on Alzheimer’s and Parkinson’s Disease (ADPD) 2019